CALCA and cutaneous mastocytosis: Methods: This was a single-center prospective cohort study that includes patients with chronic migraine (CM) or high frequency episodic migraine (HFEM) and multiple preventive treatment failures who received anti-CGRP mAbs (erenumab, galcanezumab or fremanezumab).